Sustained effect of zinc-protamin-glucagon in hyperlipidaemic patients.
Is is well known from laboratory investigations and acute intervention studies that glucagon is involved in lipid metabolism. The present study was undertaken in order to evaluate a possible sustained effect of zinc-protamin-glucagon in moderately hyperlipidaemic patients. 4 patients were investigated after an acute bolus dose of glucagon 5 mg intravenously and 16 patients were given zinc-protamin-glucagon 5 mg subcutaneously, b.i.d. for 5 days. A similar degree of decrease of plasma cholesterol and triglycerides was obtained in the acute and chronic study, while the increase in fasting blood sugar and plasma insulin seen in the acute study was not present after 5 days treatment. The effect on plasma triglycerides was much more variable than the effect on plasma cholesterol. Five days after treatment the lipid concentrations had returned to the pretreatment values. The effect could not be predicted from the pretreatment lipid concentrations, neither by the type of hyperlipidaemia present. The decrease in plasma cholesterol and triglycerides were not correlated. The drug might prove useful in the long term research of lipid metabolism and the various complex hormonal interactions.
D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005934:Glucagon / Q000008:administration & dosage*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D011479:Protamines / Q000008:administration & dosage*; D014280:Triglycerides / Q000097:blood; D015032:Zinc / Q000008:administration & dosage*
D001786:Blood Glucose; D004338:Drug Combinations; D008055:Lipids; D011479:Protamines; D014280:Triglycerides; D005934:Glucagon; D002784:Cholesterol; D015032:Zinc